GENE ONLINE|News &
Opinion
Blog

2021-10-13| LicensingSpecial

Takeda Inks $3.6 Billion Deal with Poseida to Advance Non-Viral Gene Therapies and Overcome Safety Issues

by Rajaneesh K. Gopinath
Share To
Takeda seems to have embarked on a deal-making binge in the past few days. Just last week, the Japanese pharma giant signed a billion-dollar strategic partnership with Selecta Biosciences to develop targeted gene therapies for lysosomal storage disorders. Yesterday, it emulated that with another massive deal!

On October 11th, Takeda announced a $3.6 billion gene therapy pact with San Diego-based Poseida Therapeutics. The exclusive license agreement aims to utilize Poseida's proprietary technologies for the research and development of up to eight gene therapies.

Speaking to GeneOnline, Eric Ostertag, CEO of Poseida Therapeutics, said both companies are philosophically very aligned in terms of patient care and in trying to get innovative treatments to patients with unmet medical needs, primarily pediatric patients.

GO Prime with only $1.49 now

LATEST
Previewing AACR 2024 With Select Pre-Meeting Highlights
2024-03-28
Roche Delivering on Malaria Screening Solutions for Blood Donation
2024-03-28
Innovating Cancer Treatment: The Role of ADC Technology at Nona Biosciences
2024-03-28
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
Galderma’s Strong European IPO Debut
2024-03-26
Markets and Mergers: Boston Scientific and Axonics Shake Hands on Deal
2024-03-25
Discover the Next Billion-Dollar Unicorn at the Biotech Innovation Funding Networking Event
2024-03-21
EVENT
2024-04-06
Biotech Innovation Funding Networking
Los Angeles, USA
Scroll to Top